查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083668

血漿分餾市場：按產品類型、分離方法、應用和最終用戶分類的全球市場預測 – 2026–2032 年

Plasma Fractionation Market by Product Type, Method of Fractionation, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血漿分餾市場規模將達到 782.8 億美元，複合年成長率為 9.97%。

主要市場統計數據
基準年 2025 402.2億美元
預計年份：2026年 440.5億美元
預測年份 2032 782.8億美元
複合年成長率 (%) 9.97%

血漿分餾是將捐贈的人血漿轉化為血漿衍生藥物的過程，這些藥物包括免疫球蛋白、白蛋白、凝血因子、蛋白酶抑制劑以及用於免疫學、血液學、神經病學、重症監護、創傷治療和罕見疾病管理的特效治療藥物。這些生物製藥由人類血漿蛋白製成，由於無法完全被傳統的小分子藥物取代，因此在臨床上仍然至關重要。

該領域在結構上極易受到供應波動的影響，因為生產依賴於合格血漿的採集、嚴格的捐血者合格篩檢、檢驗的病原體減少和病毒去活化、低溫運輸完整性以及受監管的生產產量。需求主要來自實證治療指引指導下，免疫球蛋白療法在已確診的原發性免疫力缺乏、免疫介導的神經系統疾病、血友病、肝病、燒傷、休克及其他疾病的臨床應用日益廣泛。

血漿分餾產業的變革性變化

血漿分餾的格局正從單純擴大產能轉向建構具有韌性的、地域分散的供應鏈。各國政府、血液供給機構和生產者正優先考慮血漿自給自足、建立長期的血液採集夥伴關係、實施捐血者維繫計畫以及提升血漿分離能力，以降低捐血者短缺、物流中斷和跨境依賴的風險。

人工智慧對血漿分餾的累積影響

人工智慧 (AI) 在捐血捐贈者管理、生產計畫、品質保證、物流和藥品安全監測等領域發揮日益重要的作用。 AI 驅動的分析可以幫助最佳化捐血預約、建立捐血留存模型、檢測批次偏差、分配庫存、監控低溫運輸、維護設備，並從上市後安全數據中識別不利事件的早期徵兆。

全球血漿分餾的關鍵區域見解

北美地區憑藉其完善的血漿採集基礎設施、成熟的報銷機制、先進的專業醫療網路以及全球血漿分離技術專家的集中，仍然是至關重要的地區。美國擁有眾多捐血中心，並積極使用免疫球蛋白，而加拿大則繼續優先透過受監管的血液和血漿系統確保安全取得。在歐洲，成熟的臨床應用以及國家和地區監管機構的嚴格監管，使得歐盟、英國和其他歐洲市場的政策討論日益重視戰略自主、捐血者安全、可追溯性以及可靠獲取必需血漿衍生藥物。

血漿分餾需求的關鍵群體分析

歐盟在有關監管協調、捐血安全標準、藥物安全監測以及血漿衍生療法自給自足的政策討論中發揮核心作用。七國集團（G7）透過成熟的醫療保健體系、專科網路、罕見疾病診斷、生物製藥保險覆蓋以及免疫球蛋白、白蛋白和凝血療法的高臨床應用率來支持高需求。在北約成員國，血漿衍生療法在醫療保健體系發展、緊急應變和衛生安全方面的重要性日益凸顯，尤其是在創傷治療、重症監護和危機期間的物資供應保障方面。

主要國家血漿分餾趨勢

美國是全球原始血漿採集中心，也是免疫球蛋白療法的主要使用國。這得益於其專業的藥房管道、免疫力缺乏的診斷以及在臨床實踐中的廣泛應用。加拿大透過其國家血液和血漿管理系統，強調穩定的供應和規範的取得途徑。在墨西哥和巴西，由於專業醫療保健的擴張、公共衛生部門的採購以及人們對免疫力缺乏和血液疾病的認知提高，需求正在成長。在歐洲，英國、德國、法國、義大利和西班牙仍然是重要的血漿分餾市場，這得益於其全民醫療保健體系、臨床指南、醫院網路以及免疫球蛋白、白蛋白和凝血因子的成熟應用。

為血漿分餾產業領導者提供的實用建議

產業領導企業應透過多元化採集網路、與捐血者建立長期合作關係、數位化預約管理、捐血者教育、符合倫理的招募流程以及緊急時應對計畫來增強血漿供應的韌性。隨著監管機構和醫療服務提供者將可靠性、可追溯性和不間斷供應放在首位，對血漿分離率、病原體安全性、低溫運輸可視性、自動化品管系統、檢驗的分析方法以及生產冗餘方面的投資仍然至關重要。

血漿分餾分析的調查方法

本執行摘要綜合運用了公開的監管指南、臨床文獻、衛生機構資料、報銷政策、捐血者和血液系統資訊、生產商資訊披露以及觀察到的行業投資模式等多種資訊來源。資訊來源通常包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、國家血液機構、藥品安全監測資料庫、同行檢驗期刊以及經審計的公開報告等權威。

關於血漿分餾未來發展的結論

隨著對免疫球蛋白、白蛋白、凝血因子、蛋白酶抑制劑和特種血漿療法的需求與罕見疾病治療、緊急醫療、醫療安全以及生技藥品生產的韌性密切相關，血漿分餾的重要性日益凸顯。該領域的未來發展將取決於血漿供應狀況、捐血安全、監管力度、產品療效證據以及維持可靠供應鏈的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章血漿分餾市場：依產品類型分類

  • 白蛋白
  • 凝血因子濃縮物
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白
  • 蛋白酶抑制劑

第8章：血漿分餾市場：依分離法分類

  • 離心分離
  • 冷沉澱
  • 乙醇沉澱法
  • 離子交換層析法
  • 超過濾

第9章：血漿分餾市場：依應用領域分類

  • 血液學
  • 神經病學
  • 腫瘤學
  • 風濕病學

第10章：血漿分餾市場：依最終用戶分類

  • 學術機構
  • 臨床研究實驗室
  • 醫院和診所

第11章血漿分餾市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章血漿分餾市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章血漿分餾市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • 3M Company
  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Ltd.
  • Biotest AG by Grifols, SA
  • China Biologic Products, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GC Biopharma corp.
  • HEINKEL Process Technology GmbH
  • Hemarus Therapeutics Ltd
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Merck KGaA
  • Octapharma AG
  • PlasmaGen BioSciences Pvt. Ltd.
  • Prothya Biosolutions BV
  • Shanghai Raas Blood Products Co. Ltd.
  • SK Plasma Co.,Ltd.
  • STERIS plc
  • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-4312A385A58A

The Plasma Fractionation Market is projected to grow by USD 78.28 billion at a CAGR of 9.97% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.22 billion
Estimated Year [2026] USD 44.05 billion
Forecast Year [2032] USD 78.28 billion
CAGR (%) 9.97%

Plasma fractionation converts donated human plasma into plasma-derived medicinal products, including immunoglobulins, albumin, coagulation factors, protease inhibitors, and specialty therapies used across immunology, hematology, neurology, critical care, trauma care, and rare disease management. These biologics remain clinically essential because they are manufactured from human plasma proteins and cannot be fully substituted by conventional small-molecule medicines.

The sector is structurally supply-sensitive because output depends on qualified plasma collection, strict donor eligibility screening, validated pathogen reduction and viral inactivation, cold-chain integrity, and regulated manufacturing yield. Demand is anchored in diagnosed primary immunodeficiency, immune-mediated neurological disorders, hemophilia, liver disease, burns, shock, and expanding clinical use of immunoglobulin therapy under evidence-based treatment guidelines.

Transformative Shifts in the Plasma Fractionation Landscape

The plasma fractionation landscape is shifting from capacity expansion alone toward resilient, regionally diversified supply chains. Governments, blood systems, and manufacturers are prioritizing plasma self-sufficiency, long-term collection partnerships, donor retention programs, and upgraded fractionation capacity to reduce exposure to donor shortages, logistics disruption, and cross-border dependency.

Clinical practice is also evolving. Subcutaneous immunoglobulin, extended-half-life coagulation therapies, improved pathogen safety technologies, better rare disease diagnosis, and broader neurologic indications are changing product mix. At the same time, regulatory scrutiny, hemovigilance, traceability requirements, environmental expectations, and sustainability reporting are raising the operating bar for plasma collection centers and global plasma fractionation facilities.

Cumulative Impact of Artificial Intelligence on Plasma Fractionation

Artificial intelligence is increasingly relevant across donor operations, production planning, quality assurance, logistics, and pharmacovigilance. AI-enabled analytics can support donor appointment optimization, donor retention modeling, batch deviation detection, inventory allocation, cold-chain monitoring, equipment maintenance, and early identification of adverse event signals from post-marketing safety data.

In a highly regulated biologics environment, AI adoption must remain validated, explainable, and compliant with GxP, data integrity, privacy, cybersecurity, and medical product safety requirements. The strongest use cases augment expert decision-making rather than replace it, improving consistency, speed, documentation quality, and risk visibility across the plasma value chain from collection to patient access.

Key Regional Insights Across Global Plasma Fractionation

North America remains pivotal due to its extensive source plasma collection infrastructure, established reimbursement pathways, advanced specialty care networks, and concentration of global fractionation expertise. The United States has a large donor-center base and strong immunoglobulin utilization, while Canada continues to emphasize secure access through regulated blood and plasma systems. Europe combines mature clinical adoption with strong oversight from national agencies and regional regulators, and policy discussions increasingly emphasize strategic autonomy, donor safety, traceability, and secure access to critical plasma-derived medicinal products across the European Union, the United Kingdom, and other European markets.

Asia-Pacific is expanding through rising diagnosis rates, hospital infrastructure investment, aging populations, and government interest in domestic plasma collection and fractionation capacity, particularly in China, India, Japan, South Korea, and Australia. Latin America is advancing through Brazil- and Mexico-led specialty care demand, with access shaped by public procurement, reimbursement policies, and import dependency. The Middle East, especially GCC states, is investing in healthcare modernization, national specialty treatment programs, and secure procurement channels. Africa remains underpenetrated, with access constrained by affordability, diagnostic availability, cold-chain capacity, plasma collection infrastructure, and reliance on imported plasma-derived therapies.

Key Group Insights for Plasma Fractionation Demand

The European Union is central to regulatory harmonization, donor safety standards, pharmacovigilance, and policy discussions on plasma self-sufficiency for plasma-derived medicinal products. G7 countries anchor advanced demand through mature healthcare systems, specialist physician networks, rare disease diagnosis, biologics reimbursement, and high clinical use of immunoglobulin, albumin, and coagulation therapies. NATO countries increasingly view plasma-derived therapies through the lens of medical preparedness, emergency response, and health security, particularly for trauma care, critical care, and continuity of supply during crises.

BRICS economies represent an important structural growth pathway as China, India, Brazil, Russia, and South Africa expand healthcare access, diagnostics, and domestic biomanufacturing capabilities. ASEAN markets are progressing through hospital upgrades, private healthcare growth, national insurance expansion, and stronger specialty care capacity, although access remains uneven across member states. GCC countries are accelerating centralized procurement, local partnerships, healthcare infrastructure investment, and national programs intended to reduce dependence on imported plasma products while improving access to immunology, hematology, and critical care therapies.

Key Country Insights in Plasma Fractionation

The United States is the global center of source plasma collection and a leading user of immunoglobulin therapy, supported by specialty pharmacy channels, diagnosis of immune deficiencies, and broad clinical adoption. Canada emphasizes secure supply and regulated access through national blood and plasma governance. Mexico and Brazil show rising demand tied to expanding specialty care, public health procurement, and improved recognition of immunodeficiency and hematology conditions. In Europe, the United Kingdom, Germany, France, Italy, and Spain remain important plasma fractionation markets supported by universal healthcare structures, clinical guidelines, hospital networks, and established use of immunoglobulins, albumin, and coagulation factors.

Russia maintains domestic production priorities and seeks to strengthen supply security, while China is scaling plasma collection, fractionation capacity, and diagnosis of immune-mediated diseases under close regulatory oversight. India is advancing through hospital expansion, growing critical care needs, and increasing attention to domestic plasma utilization, though collection and access remain development priorities. Japan, Australia, and South Korea combine advanced regulation, high clinical standards, aging populations, and strong hospital systems, supporting demand for immunoglobulin, albumin, coagulation products, and specialty plasma therapies used in complex disease management.

Actionable Recommendations for Plasma Fractionation Leaders

Industry leaders should strengthen plasma supply resilience through diversified collection networks, long-term donor engagement, digital scheduling, donor education, ethical recruitment practices, and contingency planning. Investment in fractionation yield, pathogen safety, cold-chain visibility, automated quality systems, validated analytics, and manufacturing redundancy remains essential as regulators and healthcare providers prioritize reliability, traceability, and uninterrupted access.

Commercial strategies should align product portfolios with immunoglobulin demand, albumin access, rare disease diagnosis, hemophilia care, and regional plasma self-sufficiency programs. Leaders should deploy validated AI, expand clinician education, support earlier diagnosis, pursue strategic public-private partnerships, and build transparent evidence packages that support reimbursement, patient access, tender success, and differentiated value in plasma-derived medicinal products.

Research Methodology for Plasma Fractionation Analysis

This executive summary is developed through triangulation of public regulatory guidance, clinical literature, health agency materials, reimbursement context, donor and blood system information, manufacturing disclosures, and observed industry investment patterns. Sources typically include authorities such as the FDA, EMA, WHO, national blood agencies, pharmacovigilance databases, peer-reviewed journals, and audited public reporting.

The methodology emphasizes verified, data-backed signals over speculative claims. Insights are evaluated across product type, therapeutic use, plasma collection capacity, manufacturing footprint, quality and safety requirements, regional access, public policy direction, reimbursement conditions, and competitive strategy to provide an objective view of the plasma fractionation ecosystem without relying on market sizing or forecasting.

Conclusion on the Future of Plasma Fractionation

Plasma fractionation is becoming more strategic as demand for immunoglobulins, albumin, coagulation factors, protease inhibitors, and specialty plasma therapies intersects with rare disease care, critical care, health security, and biologics manufacturing resilience. The sector's future will be shaped by plasma availability, donor safety, regulatory discipline, product evidence, and the ability to maintain trusted supply chains.

The strongest organizations will combine reliable plasma sourcing, operational excellence, validated digital intelligence, robust quality systems, and patient-centered access strategies. As regional self-sufficiency initiatives and healthcare preparedness priorities accelerate, the industry will increasingly reward stakeholders capable of delivering safe, reliable, traceable, and evidence-supported plasma-derived medicines across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Plasma Fractionation Market, by Product Type

  • 7.1. Albumin
  • 7.2. Coagulation Factor Concentrates
  • 7.3. Immunoglobulins
    • 7.3.1. Intravenous Immunoglobulin
    • 7.3.2. Subcutaneous Immunoglobulin
  • 7.4. Protease Inhibitors

8. Plasma Fractionation Market, by Method of Fractionation

  • 8.1. Centrifugation
  • 8.2. Cryoprecipitation
  • 8.3. Ethanol Precipitation
  • 8.4. Ion-Exchange Chromatography
  • 8.5. Ultrafiltration

9. Plasma Fractionation Market, by Application

  • 9.1. Hematology
  • 9.2. Neurology
  • 9.3. Oncology
  • 9.4. Rheumatology

10. Plasma Fractionation Market, by End-User

  • 10.1. Academic Institutions
  • 10.2. Clinical Research Laboratories
  • 10.3. Hospitals & Clinics

11. Plasma Fractionation Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Plasma Fractionation Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Plasma Fractionation Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. 3M Company
  • 15.2. ADMA Biologics, Inc.
  • 15.3. Bharat Serums and Vaccines Limited
  • 15.4. Bio Products Laboratory Ltd.
  • 15.5. Biotest AG by Grifols, S.A.
  • 15.6. China Biologic Products, Inc.
  • 15.7. CSL Limited
  • 15.8. Emergent BioSolutions Inc.
  • 15.9. GC Biopharma corp.
  • 15.10. HEINKEL Process Technology GmbH
  • 15.11. Hemarus Therapeutics Ltd
  • 15.12. Intas Pharmaceuticals Ltd.
  • 15.13. Kamada Ltd.
  • 15.14. Kedrion S.p.A.
  • 15.15. LFB SA
  • 15.16. Merck KGaA
  • 15.17. Octapharma AG
  • 15.18. PlasmaGen BioSciences Pvt. Ltd.
  • 15.19. Prothya Biosolutions B.V.
  • 15.20. Shanghai Raas Blood Products Co. Ltd.
  • 15.21. SK Plasma Co.,Ltd.
  • 15.22. STERIS plc
  • 15.23. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA FRACTIONATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PLASMA FRACTIONATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALBUMIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALBUMIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALBUMIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CENTRIFUGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRIFUGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CENTRIFUGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRYOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ETHANOL PRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ETHANOL PRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ETHANOL PRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ION-EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ION-EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ION-EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ULTRAFILTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRAFILTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRAFILTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. CANADA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 144. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. MEXICO PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 150. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRAZIL PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 156. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. GERMANY PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 168. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 174. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 175. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. RUSSIA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 180. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 181. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 186. ITALY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 187. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. SPAIN PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 192. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 193. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 204. INDIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 216. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 222. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)